Cardiovascular Systems Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cardiovascular Systems stock.
View analyst ratings for Cardiovascular Systems or view top-rated stocks.

Wall Street analysts have given Cardiovascular Systems a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cardiovascular Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Cardiovascular Systems.

Cardiovascular Systems, Inc. (NASDAQ:CSII) released its quarterly earnings data on Wednesday, November, 4th. The medical device company reported ($0.05) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.18. The medical device company earned $60.54 million during the quarter, compared to analyst estimates of $56.27 million. Cardiovascular Systems had a negative net margin of 10.12% and a negative trailing twelve-month return on equity of 11.43%.
View Cardiovascular Systems' earnings history.

Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CSII shares have increased by 13.9% and is now trading at $41.37.
View which stocks have been most impacted by COVID-19.

Cardiovascular Systems updated its third quarter 2021 After-Hours earnings guidance on Wednesday, February, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $69.27 million.

7 Wall Street analysts have issued 12-month price targets for Cardiovascular Systems' stock. Their forecasts range from $45.00 to $50.00. On average, they anticipate Cardiovascular Systems' share price to reach $47.43 in the next year. This suggests a possible upside of 14.6% from the stock's current price.
View analysts' price targets for Cardiovascular Systems or view top-rated stocks among Wall Street analysts.

12 employees have rated Cardiovascular Systems CEO Scott Ward on Glassdoor.com. Scott Ward has an approval rating of 81% among Cardiovascular Systems' employees.

Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD) and Varian Medical Systems (VAR).
View all of CSII's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), (XEL), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and The Procter & Gamble (PG).

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Cardiovascular Systems' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.37%), Brown Capital Management LLC (14.90%), Janus Henderson Group PLC (3.41%), Renaissance Technologies LLC (3.18%), New York State Common Retirement Fund (1.97%) and Northern Trust Corp (1.30%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb and Sandra Sedo.
View institutional ownership trends for Cardiovascular Systems.

CSII stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Peregrine Capital Management LLC, Aviva PLC, Frontier Capital Management Co. LLC, Rice Hall James & Associates LLC, Comerica Bank, Squarepoint Ops LLC, and Barclays PLC. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, and Sandra Sedo.
View insider buying and selling activity for Cardiovascular Systems or view top insider-selling stocks.

CSII stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Morgan Stanley, Walleye Capital LLC, Dimensional Fund Advisors LP, Assenagon Asset Management S.A., Canada Pension Plan Investment Board, and Exchange Traded Concepts LLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Erik Paulsen, Martha Goldberg Aronson, and Rhonda J Robb.
View insider buying and selling activity for Cardiovascular Systems or or view top insider-buying stocks.

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CSII stock can currently be purchased for approximately $41.37.

Cardiovascular Systems has a market capitalization of $1.66 billion and generates $236.54 million in revenue each year. The medical device company earns $-27,240,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

Cardiovascular Systems employs 779 workers across the globe.

The official website for Cardiovascular Systems is www.csi360.com.

Cardiovascular Systems is headquartered at 1225 OLD HWY 8 NW, ST. PAUL MN, 55112.

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]